Drug intelligence / Profile preview

BAT2306

Development stage: Phase 3
Lead developer: Bio-Thera Solutions
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

BAT2306 is a proposed biosimilar of Novartis' Cosentyx® (secukinumab). It is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A. BAT2306 is being developed by Bio-Thera Solutions for the treatment of moderate to severe plaque psoriasis and other autoimmune disorders. The drug has completed a Phase I study and is currently in Phase III clinical trials comparing its efficacy and safety to Cosentyx in patients with moderate to severe plaque psoriasis.

Other names: secukinumab biosimilar

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on BAT2306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAT2306.

Explore the full profile